Literature DB >> 7671373

Superficial accumulation of plasminogen during plasma clot lysis.

D V Sakharov1, D C Rijken.   

Abstract

BACKGROUND: Binding of plasminogen to partially degraded fibrin is an important step in fibrinolysis, influencing its rate and fibrin specificity. Little is known about the spatial distribution of plasminogen and of plasminogen-binding sites inside thrombi during lysis. In the present study, we investigated this problem, which is important for a better understanding of the local regulation of fibrinolysis and the rate-limiting factors of therapeutic thrombolysis. METHODS AND
RESULTS: An experimental system was used that allowed continuous visualization and quantification by fluorescence microscopy of the spatial distribution of fluorescein-labeled plasminogen inside and outside model thrombi. Strong superficial accumulation of plasminogen was observed during lysis of a plasma clot induced by tissue-type or urokinase-type plasminogen activators in the surrounding plasma. A distinctly visible plasminogen-accumulating shell moved continuously with the reducing surface of the clot. The accumulation decreased in conditions of exhaustive activation of plasminogen in the outer plasma. It was found in a purified system that a thin superficial layer (approximately 50 microns wide) of a plasmin-treated fibrin clot exposes about 2.5 plasminogen-binding sites per fibrin monomer with a Kd of 2.2 mumol/L. At a physiological concentration of plasminogen (1.5 mumol/L) in the outer medium, plasminogen was concentrated about 10-fold in this layer. The binding was dose-dependently inhibited by epsilon-aminocaproic acid.
CONCLUSIONS: We conclude that the generation of potent surface-associated plasminogen-binding sites during thrombolysis results in a strikingly high plasminogen concentration at the dynamically changing surface of a lysing clot. The necessity of a continuous plasminogen supply from the plasma supports the use of fibrin-specific and plasminogen-sparing agents for thrombolytic therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671373     DOI: 10.1161/01.cir.92.7.1883

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

Review 1.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 2.  Interventional Therapy for Upper Extremity Deep Vein Thrombosis.

Authors:  Timothy A Carlon; Deepak Sudheendra
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

3.  Fibrinogen counteracts the antiadhesive effect of fibrin-bound plasminogen by preventing its activation by adherent U937 monocytic cells.

Authors:  V K Lishko; I S Yermolenko; H Owaynat; T P Ugarova
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

4.  Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.

Authors:  Xiang Fan; Zhanyang Yu; Jianxiang Liu; Ning Liu; Katherine A Hajjar; Karen L Furie; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 5.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

6.  Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Kristina Danielyan; Juan-Carlos Murciano; Kumkum Ganguly; Tatiana Krasik; Ronald P Taylor; Steven Pincus; Steven Jones; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

7.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

8.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

9.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

10.  Plasminogen on the surfaces of fibrin clots prevents adhesion of leukocytes and platelets.

Authors:  V K Lishko; I S Yermolenko; T P Ugarova
Journal:  J Thromb Haemost       Date:  2009-01-22       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.